

Notice of Allowability	Application No.	Applicant(s)	
	09/976,617	MIRKIN ET AL.	
	Examiner	Art Unit	
	Jezia Riley	1637	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to Amdt filed 8/14/03.
2. ☒ The allowed claim(s) is/are 433-489.
3. ☐ The drawings filed on _____ are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
- * Certified copies not received: _____.
5. ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
 - (a) ☐ The translation of the foreign language provisional application has been received.
6. ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. **THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

7. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
8. ☒ CORRECTED DRAWINGS must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No. _____.
 - (b) ☐ including changes required by the proposed drawing correction filed _____, which has been approved by the Examiner.
 - (c) ☒ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No. _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet.

9. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|--|--|
| 1 <input type="checkbox"/> Notice of References Cited (PTO-892) | 2 <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3 <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 4 <input type="checkbox"/> Interview Summary (PTO-413), Paper No. _____. |
| 5 <input checked="" type="checkbox"/> Information Disclosure Statements (PTO-1449), Paper No. _____. | 6 <input type="checkbox"/> Examiner's Amendment/Comment |
| 7 <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit of Biological Material | 8 <input type="checkbox"/> Examiner's Statement of Reasons for Allowance |
| | 9 <input type="checkbox"/> Other |

Art Unit: 1637


An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The formal Drawings are required.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jezia Riley whose telephone number is 703-305-6855. The examiner can normally be reached on 9:30AM - 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 703-308-1119. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.


JEZIA RILEY
PRIMARY EXAMINER

10/29/03

ALLOWED CLAIMS/ TJ

433. (New) A method of nanofabrication comprising

providing at least one type of linking oligonucleotide having a selected sequence,
the sequence of each type of linking oligonucleotide having at least two portions;

providing one or more types of nanoparticles having oligonucleotides bound
thereto, wherein the oligonucleotides are present on a surface of the nanoparticles at a surface
density of at least 10 picomoles/cm², at least some of the oligonucleotides on each type of
nanoparticles comprise at least one type of recognition oligonucleotides, each type of recognition
oligonucleotides comprises a spacer portion and a recognition portion, the spacer portion being
designed so that it is bound to the nanoparticles, the recognition portion comprises a sequence
complementary to at least a portion of the sequence of a specific type of linking oligonucleotide;
and

contacting the linking oligonucleotides and nanoparticles under conditions
effective to allow hybridization of at least a portion of the oligonucleotides on the nanoparticles
to the linking oligonucleotides so that a desired nanomaterial or nanostructure is formed.

434. (New) The method of Claim 433 wherein the linking oligonucleotide is single-
stranded.

435. (New) The method of Claim 433 wherein the linking oligonucleotide is double-
stranded and has overhanging ends.

436. (New) The method of Claim 433 wherein the linking oligonucleotide is a triple-
stranded oligonucleotide connector.

437. (New) The method of Claim 433 wherein the linking oligonucleotide comprises a
peptide nucleic acid chain.

438. (New) A method of nanofabrication comprising:

providing at least two types of nanoparticles having oligonucleotides bound thereto wherein the oligonucleotides are present on a surface of the nanoparticles at a surface density of at least 10 picomoles/cm², wherein at least some of the oligonucleotides on each type of nanoparticles comprise one or more types of recognition oligonucleotides, each type of recognition oligonucleotides comprises a spacer portion and a recognition portion, the spacer portion being designed so that it is bound to the nanoparticles, at least one type of recognition oligonucleotides on a first type of nanoparticles comprises a recognition portion having a sequence complementary to at least a portion of the oligonucleotides on a second type of nanoparticles and at least one type of recognition oligonucleotides on the second type of nanoparticles comprises a recognition portion having a sequence complementary to at least a portion of the oligonucleotides on the first type of nanoparticles; and

contacting the first and second types of nanoparticles under conditions effective to allow hybridization of at least a portion of the oligonucleotides on the nanoparticles to each other so that a desired nanomaterial or nanostructure is formed.

439. (New) The method of any one of Claims 433 or 438 wherein the oligonucleotides are attached to the nanoparticles in a stepwise ageing process comprising (i) contacting the oligonucleotides with the nanoparticles in a first aqueous solution for a period of time sufficient to allow some of the oligonucleotides to bind to the nanoparticles; (ii) adding at least one salt to the first aqueous solution to create a second aqueous solution; and (iii) contacting the oligonucleotides and nanoparticles in the second aqueous solution for an additional period of time to enable additional oligonucleotides to bind to the nanoparticles.